ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.71 Million EUR | -7.03% |
| 2022 | 15.82 Million EUR | -27.52% |
| 2021 | 21.83 Million EUR | 112.21% |
| 2020 | 10.28 Million EUR | 0.38% |
| 2019 | 10.24 Million EUR | -21.97% |
| 2018 | 13.13 Million EUR | -28.21% |
| 2017 | 18.29 Million EUR | -37.05% |
| 2016 | 29.06 Million EUR | -36.96% |
| 2015 | 46.1 Million EUR | 325.46% |
| 2014 | 10.83 Million EUR | -22.18% |
| 2013 | 13.92 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 15.33 Million EUR | 0.0% |
| 2023 Q1 | 13.83 Million EUR | -12.58% |
| 2023 Q3 | 14.83 Million EUR | 7.24% |
| 2023 Q4 | 14.71 Million EUR | -0.84% |
| 2023 FY | 14.71 Million EUR | -7.03% |
| 2023 Q2 | 13.83 Million EUR | 0.0% |
| 2022 Q2 | 18.17 Million EUR | 0.0% |
| 2022 Q3 | 15.82 Million EUR | -12.95% |
| 2022 FY | 15.82 Million EUR | -27.52% |
| 2022 Q1 | 18.17 Million EUR | -16.74% |
| 2022 Q4 | 15.82 Million EUR | 0.0% |
| 2021 Q4 | 21.83 Million EUR | 0.0% |
| 2021 FY | 21.83 Million EUR | 112.21% |
| 2021 Q3 | 21.83 Million EUR | 203.9% |
| 2021 Q2 | 7.18 Million EUR | 0.0% |
| 2021 Q1 | 7.18 Million EUR | -30.17% |
| 2020 Q1 | 9.2 Million EUR | -10.17% |
| 2020 Q3 | 10.28 Million EUR | 11.74% |
| 2020 Q4 | 10.28 Million EUR | 0.0% |
| 2020 Q2 | 9.2 Million EUR | 0.0% |
| 2020 FY | 10.28 Million EUR | 0.38% |
| 2019 Q4 | 10.24 Million EUR | 0.0% |
| 2019 Q3 | 10.24 Million EUR | -12.12% |
| 2019 Q2 | 11.66 Million EUR | 0.0% |
| 2019 Q1 | 11.66 Million EUR | -11.21% |
| 2019 FY | 10.24 Million EUR | -21.97% |
| 2018 FY | 13.13 Million EUR | -28.21% |
| 2018 Q4 | 13.13 Million EUR | 0.0% |
| 2018 Q3 | 13.13 Million EUR | -11.26% |
| 2018 Q2 | 14.8 Million EUR | 0.0% |
| 2018 Q1 | 14.8 Million EUR | -19.11% |
| 2017 Q3 | 18.29 Million EUR | -15.5% |
| 2017 Q2 | 21.65 Million EUR | 0.0% |
| 2017 Q1 | 21.65 Million EUR | -25.5% |
| 2017 FY | 18.29 Million EUR | -37.05% |
| 2017 Q4 | 18.29 Million EUR | 0.0% |
| 2016 Q2 | 37.49 Million EUR | 0.0% |
| 2016 FY | 29.06 Million EUR | -36.96% |
| 2016 Q1 | 37.49 Million EUR | -18.68% |
| 2016 Q3 | 29.06 Million EUR | -22.48% |
| 2016 Q4 | 29.06 Million EUR | 0.0% |
| 2015 Q3 | 46.1 Million EUR | -13.52% |
| 2015 Q1 | 53.31 Million EUR | 391.99% |
| 2015 Q4 | 46.1 Million EUR | 0.0% |
| 2015 FY | 46.1 Million EUR | 325.46% |
| 2015 Q2 | 53.31 Million EUR | 0.0% |
| 2014 FY | 10.83 Million EUR | -22.18% |
| 2014 Q3 | 10.83 Million EUR | 0.0% |
| 2014 Q4 | 10.83 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 13.92 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIVAX Société Anonyme | 327.06 Million EUR | 95.502% |
| Adocia SA | 24.95 Million EUR | 41.056% |
| Aelis Farma SA | 26.28 Million EUR | 44.028% |
| Biophytis S.A. | 11.93 Million EUR | -23.241% |
| Advicenne S.A. | 12.4 Million EUR | -18.562% |
| genOway Société anonyme | 31.84 Million EUR | 53.804% |
| IntegraGen SA | 8 Million EUR | -83.867% |
| Medesis Pharma S.A. | 1.92 Million EUR | -663.626% |
| Neovacs S.A. | 47.53 Million EUR | 69.053% |
| NFL Biosciences SA | 3.97 Million EUR | -270.47% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 1.361% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -292.605% |
| Sensorion SA | 46.49 Million EUR | 68.362% |
| Theranexus Société Anonyme | 7.23 Million EUR | -103.24% |
| TME Pharma N.V. | 2.49 Million EUR | -490.526% |
| Valbiotis SA | 33.24 Million EUR | 55.757% |
| TheraVet SA | 7.53 Million EUR | -95.243% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 58.298% |
| argenx SE | 4.11 Billion EUR | 99.642% |
| BioSenic S.A. | 9.55 Million EUR | -53.886% |
| Celyad Oncology SA | 16.28 Million EUR | 9.655% |
| DBV Technologies S.A. | 165.65 Million USD | 91.12% |
| Galapagos NV | 4.35 Billion EUR | 99.662% |
| Genfit S.A. | 173.87 Million EUR | 91.54% |
| GeNeuro SA | 6.31 Million EUR | -133.015% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 69.149% |
| Innate Pharma S.A. | 184.19 Million EUR | 92.014% |
| Inventiva S.A. | 69.13 Million EUR | 78.724% |
| MaaT Pharma SA | 42.93 Million EUR | 65.736% |
| MedinCell S.A. | 36.94 Million EUR | 60.187% |
| Nanobiotix S.A. | 93.89 Million EUR | 84.334% |
| Onward Medical N.V. | 43.62 Million EUR | 66.284% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 86.239% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 82.039% |
| Oxurion NV | 6.55 Million EUR | -124.58% |
| Pharming Group N.V. | 426.33 Million EUR | 96.55% |
| Poxel S.A. | 4.82 Million EUR | -204.997% |
| GenSight Biologics S.A. | 9.08 Million EUR | -61.88% |
| Transgene SA | 45.21 Million EUR | 67.468% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.234% |
| UCB SA | 15.53 Billion EUR | 99.905% |
| Valneva SE | 469.39 Million EUR | 96.866% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 52.285% |